From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Systematic (IUPAC) name
2-sec-Butyl-2-methylpropane-1,3-diyl dicarbamate
Clinical data
Legal status
CAS Number 64-55-1 N
ATC code N05BC04 (WHO)
PubChem CID: 6151
ChemSpider 5919 N
KEGG D01807 YesY
Chemical data
Formula C10H20N2O4
Molecular mass 232.277 g/mol
 NYesY (what is this?)  (verify)

Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class.[1][2] It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.[3]

Mebutamate is one of many GABAergic drugs which act via allosteric agonism of the GABAA receptor at the β-subreceptor similar to barbiturates. In contrast, benzodiazepines act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.

Other carbamates with the same mechanism of action and pharmacological properties include meprobamate, carisoprodol, felbamate, and tybamate).


File:Mebutamate synthesis.svg
Mebutamate synthesis: Berger, Ludwig, U.S. Patent 2,878,280 (1959 to Carter Prod.).

Structural analogs


  1. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. p. 634. ISBN 978-3-88763-075-1.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  2. The Merck Index (14 ed.). Merck Publishers. 5813. ISBN 978-0-911910-00-1.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>
  3. Lua error in Module:Citation/CS1/Identifiers at line 47: attempt to index field 'wikibase' (a nil value).